Objective-The atherosclerotic lesion is characterized by lipid peroxide accumulation. Paraoxonase 1 (PON1) reduces atherosclerotic lesion oxidative stress, whereas urokinase-type plasminogen activator (uPA) increases oxidative stress in atherosclerotic lesions and contributes to the progression and complications of atherosclerosis. We hypothesized that uPA may promote oxidative stress in the arterial wall via modulation of PON1 activity. Because the liver is the main site for PON1 production, in the present study, we tested whether uPA influences PON1 expression in hepatocytes. Methods and Results-HuH7 hepatocytes were incubated in culture with increasing concentrations of uPA. uPA decreased PON1 gene expression and activity in a dose-dependent manner and accordingly suppressed PON1 secretion from hepatocytes. This effect required uPA/uPA receptor interaction. uPA downregulated PON1 gene expression via inactivation of peroxisome proliferator-activated receptor-␥ (PPAR␥) activity, and this effect was dependent on uPA-mediated mitogen-activated protein kinase kinase activation. Mechanistic studies showed that uPA enhanced mitogen-activated protein kinase kinase-PPAR␥ interaction, resulting in PPAR␥ nuclear export to the cytosol. 
T he atherosclerotic lesion is dominated by accumulation of lipid peroxides, along with the progression of early plaque development. 1 Paraoxonase 1 (PON1) is a calciumdependent, high-density lipoprotein (HDL)-bound lipolactonase with antioxidative properties, which are associated with the enzyme's capability to decrease oxidative stress in atherosclerotic lesions 2 and to attenuate atherosclerosis development. Immunohistochemical analysis has revealed accumulation of PON1 in the human atherosclerotic lesion as it progresses from fatty streak to advanced lesion. 3 Recently, it was demonstrated that PON1 acts to reduce the oxidizing potency of lipids in atherosclerotic lesions, thus providing protection against oxidation. 4 Epidemiological evidence demonstrates that low PON1 activity is associated with increased risk of cardiovascular events and cardiovascular disease 5 and is an independent risk factor for coronary artery disease. 6 A primary determinant of serum PON1 levels is the availability of the enzyme for release by the liver, the principal site of PON1 production. 7 Urokinase-type plasminogen activator (uPA) is a serine protease enzyme of the fibrinolytic system, and uPA binding to its receptor (uPAR) is implicated in plasmin generation. The uPA/uPAR system has also a nonproteolytic role that extends beyond its role in fibrinolysis. 8 uPA is expressed in human atherosclerotic vessel wall, mainly in association with macrophages, 9 and uPA overexpression contributes to the progression and complications of atherosclerosis. 10 We have recently shown that uPA enhanced macrophage atherogenicity by increasing cellular cholesterol accumulation. 11 Increased plasma levels of uPA are associated with plaque rupture. 12 uPA was shown to promote oxidative stress in vascular smooth muscle cells 13, 14 and in macrophages. 15 However, information on possible mechanisms responsible for uPA-mediated increase in oxidative stress is very limited. We have demonstrated that in macrophages, uPA activates the NADPH oxidase complex, resulting in reactive oxygen species production, 15 and increases the expression of macrophage paraoxonase 2 (PON2), another member of the paraoxonase family. 16 We further hypothesize that uPA may promote oxidative stress in the arterial wall, also via modulation of PON1 activity. uPA is present in a variety of cells and is known to fulfill many functions through its biological activity, including intracellular signaling from the uPA/uPAR interaction. [17] [18] [19] Because the liver is the main site for PON1 production, in the present study we have tested the hypothesis that uPA modulates PON1 expression in hepatocytes.
Materials and Methods
For detailed Material and Methods, see the Supplemental Materials (Figure legend) , available online at http://atvb.ahajournals.org.
Chemicals
Human 2-chain high molecular weight uPA activity standard and amino-terminal fragment (ATF) were from American Diagnostica Inc.
Cells
The human hepatoma cell line HuH7 was used. Primary hepatocytes were isolated from male Lewis rats.
Cell-Associated and Secreted PON1 Arylesterase Activity
Cell-associated PON1 arylesterase activity was measured directly on the cells, and secreted PON1 arylesterase activity was measured in the collected medium. Enzyme arylesterase activity was measured using phenyl acetate as substrate. The absorbance of the phenol formed was monitored at 0 minutes and 1 minute after substrate addition. Measurements were as follows: 1 U of arylesterase activityϭ1 mol of phenyl acetate hydrolyzed per minute. 20
PON1 Promoter Reporter Studies
HuH7 cells were transfected with 1 g of DNA consisting of a 20:1 ratio of PON1 promoter construct and a Renilla luciferase encoding control plasmid, respectively.
PON1 Protein Determination
PON1 protein expression was assessed by Western blotting in cell lysates using polyclonal rabbit anti-human PON1 antibody (Abcam, Cambridge, United Kingdom).
Cell Fractionation and Immunoprecipitation
Subconfluent HuH7 hepatocytes were stimulated with uPA under the specific experimental conditions. For whole cell lysate preparation, cells were lysed in situ with a lysis buffer. Cell fractionation was achieved by using the ProteoJET Cytoplasmic and Nuclear Protein Extraction Kit (No. K0311, Fermentas Life Sciences). The extracted cytoplasmic proteins were used for immunoprecipitation and then analyzed by Western blotting.
Chromatin Immunoprecipitation
Chromatin immunoprecipitation was performed as described previously. 21 
Detection of Intracellular Oxidative Stress
Intracellular oxidative stress was assayed through the oxidation of 2Ј,7Ј-dichlorofluorescin diacetate (Sigma).
Animal Studies
uPAR-deficient mice (uPARϪ/Ϫ) and corresponding C57BL/6J control mice were bred under pathogen free conditions in the animal facility of Phenos GmbH (Hannover, Germany). All these mice were male and were used at 8 to 12 weeks of age.
Serum Lipid Peroxidation
Serum derived from mice was diluted 1:4 with phosphate-buffered saline and incubated with 100 mmol/L 2,2=-azobis 2-amidinopropane hydrochloride (AAPH). Serum susceptibility to oxidation was determined by measuring thiobarbituric acid reactive substances (TBARS) formation. 22 
Statistical Analyses
Each separate experiment was performed in triplicate wells done independently, and each individual experiment was replicated at least 3 times (nϭ9). Statistical analyses used Student t test for comparing differences between the 2 groups, and 1-way ANOVA followed by the Student-Newman-Keuls test was used for comparing differences between multiple groups. PϽ0.01 and PϽ0.05 were considered statistically significant.
Results

uPA Decreases PON1 Expression and Secretion From Hepatocytes
To test whether uPA has an influence on hepatic PON1 expression, HuH7 hepatocytes were incubated with increasing concentrations of uPA for 24 hours. uPA decreased PON1 mRNA expression in a dose-dependent manner by up to 80% ( Figure 1A) . Next, cells were transfected with the PON1 reporter gene plasmid and were exposed to increasing concentrations of uPA, followed by luciferase activity measurement. uPA produced a concentration-dependent downregulation in PON1 promoter activity ( Figure 1B ). Because uPA-mediated PON1 downregulation was significantly noticed at a concentration of 10 nmol/L, we have used this concentration in all the following experiments. Next, we examined whether uPA reduces the abundance of hepatocyte PON1 protein. However, because PON1 is mostly secreted from the hepatocytes, we have pretreated the cells with monensin, which is an antibiotic that blocks intracellular protein transport and therefore inhibits secretion. 23 Supplemental Figure I shows that in the absence of monensin, PON1 protein was detected in cell medium and not in cell lysate, whereas in the presence of monensin, PON1 protein was retained in the cells. Treatment of hepatocytes with uPA significantly decreased PON1 cell-associated protein by 45% ( Figure 1C ). Furthermore, cell-associated PON1 arylesterase activity decreased by 72% ( Figure 1D ). We also measured PON1 arylesterase activity in medium (without FCS) collected from cells stimulated with uPA for 24 hours at 37°C. Because it was previously shown that PON1 secretion from cells can be effective only in the presence of an acceptor, ie, HDL, 7 we added to the incubation medium HDL, which was separated from serum derived from PON1 knockout mice, to eliminate possible interference of HDL-associated PON1 activity. uPA decreased PON1 activity in medium by 38% compared with control unstimulated cells ( Figure 1E ).
uPA Requires uPA-uPAR Interaction for Decreasing PON1 Gene Expression in Hepatocytes
We have recently shown that uPA-mediated upregulation of PON2 in macrophages requires uPA/uPAR interaction. 15 Therefore, next we determined whether uPA/uPAR interaction is required also for the effect of uPA on hepatic PON1 expression. As we could not find evidence in the literature for expression of uPAR in HuH7 hepatocytes, we measured by fluorescence-activated cell sorting the expression of uPAR on HuH7 hepatocytes. uPAR expression on monocytes served as a negative control, whereas uPAR expression on THP-1 differentiated macrophages served as a positive control. Supplemental Figure II shows that HuH7 hepatocytes indeed express uPAR in a manner similar to mature macrophages. Incubation of HuH7 hepatocytes with uPA significantly decreased PON1 mRNA expression ( Figure 2A ) and PON1 promoter activity ( Figure 2B ) by 46% and 43%, respectively. Similar results were observed on incubation of the cells with an amino-terminal fragment of uPA (ATF) that lacks catalytic activity, suggesting that binding to uPAR may be sufficient to suppress PON1 gene expression in hepatocytes. To investigate the requirement of uPA/uPAR interaction, HuH7 hepatocytes were incubated with uPA or with the ATF in the presence of a mouse anti-human uPAR blocking antibody (anti-CD87). Incubation of hepatocytes with anti-CD87 alone had no effect on PON1 expression ( Figure 2 ). Incubation of hepatocytes with uPA in the presence of anti-CD87 abolished the inhibitory effect of uPA and of the amino-terminal fragment on both PON1 mRNA expression ( Figure 2A ) and PON1 promoter activity ( Figure 2B ). These results indicate that uPA-mediated downregulation of PON1 gene expression requires uPA/uPAR interaction, suggesting activation of an intracellular signal transduction pathway.
Hepatic PON1 Gene Expression in uPAR ؊/؊ Mice
To support the in vitro findings with relevant in vivo data, we examined PON1 expression in liver tissue derived from 6 uPAR Ϫ/Ϫ mice in comparison with the corresponding C57Bl/6 control mice. PON1 mRNA abundance in liver tissue ( Figure 3A ) and PON1 arylesterase activity in mice serum ( Figure 3B ) were significantly higher, by 36% and by 57%, respectively, in uPAR Ϫ/Ϫ mice compared with the control mice. Functionally, serum oxidative stress, determined as TBARS formation in response to AAPH, was significantly decreased by 36% in uPAR Ϫ/Ϫ mice compared with the control mice ( Figure 3C ). These results support the role of uPAR in uPA-mediated downregulation of hepatic Ϫ/Ϫ mice and 6 C57Bl/6 control mice was analyzed for PON1 mRNA expression. B and C, PON1 arylesterase activity (B) and oxidative stress (C) were determined in serum harvested from 6 uPAR Ϫ/Ϫ mice and 6 C57Bl/6 control mice. Results are expressed as meanϮSD (nϭ6 mice, each assay was performed in duplicate). *PϽ0.01 uPAR Ϫ/Ϫ mice vs control mice.
PON1 expression and its contribution to the oxidative stress in serum.
uPA Increases Cellular Oxidative Stress in Hepatocytes
We have previously demonstrated that uPA upregulates PON2 expression in macrophages via promotion of cellular oxidative stress. 15 In contrast to PON2, PON1 protein expression and activity were shown to decrease under oxidative stress. 24, 25 We thus hypothesized that increased oxidative stress in hepatocytes treated with uPA might subsequently be involved in the reduction in hepatocyte PON1 expression. Therefore, we next questioned whether uPA increases cellular oxidative stress in hepatocytes. Incubation of HuH7 hepatocytes with uPA for 24 hours resulted in a significant increase in oxidative stress by 3.5-fold (see Supplemental Figure III ). As reactive oxygen species are upstream activators of mitogen-activated protein kinase kinase (MEK) 1/2, and because uPA/uPAR interaction was shown to activate MEK/ extracellular signal-regulated kinase (ERK) signaling cascade, 11, 16 we next examined whether uPA inhibits PON1 gene expression in a MEK-dependent manner.
uPA Inhibits PON1 Gene Expression in a MEK-Peroxisome Proliferator-Activated Receptor-␥-Dependent Manner
Because uPA/uPAR interaction was shown to activate MEK/ ERK signaling cascade, 11, 16 we examined whether uPA inhibits PON1 gene expression in a MEK-dependent manner. Treatment of HuH7 hepatocytes with uPA in the presence of PD98059, which is a selective MEK inhibitor, completely restored PON1 expression ( Figure 4A ), suggesting that MEK is involved in uPA downregulation of hepatocyte PON1. The small molecule inhibitor of protein kinase C, 1-(5-isoquinolinesulfonyl)-2-methylpiperazine dihydrochloride (H-7), did not abolish uPA-mediated downregulation of PON1 gene expression, thus demonstrating the specificity of MEK as part of the proposed signaling pathway. The experiment shown in Figure 4B confirmed that uPA activates MEK, because 10 minutes after uPA addition phosphorylated MEK could be detected in cell cytosols.
One downstream target of MEK is peroxisome proliferator-activated receptor-␥ (PPAR␥). We have recently shown that PON1 gene expression in hepatocytes is regulated by PPAR␥. 26 On the basis of these findings, we tested whether uPA inhibits hepatocyte PON1 expression by modulating PPAR␥ activity. HuH7 hepatocytes were treated with rosiglitazone, which is a synthetic PPAR␥ ligand, in the absence or presence of uPA. PON1 mRNA was markedly increased (by 80%) by rosiglitazone, whereas uPA had an inhibitory effect on the basal, as well as on the rosiglitazone-stimulated, PON1 mRNA expression ( Figure 4C ). These results suggest that uPA might interfere with rosiglitazone direct activation of PPAR␥. To study the direct effect of uPA on PPAR␥ transcriptional activity, HuH7 hepatocytes were cotransfected with a PPAR␥ response element-x3-tk-luciferase plasmid as a reporter of PPAR␥ genomic activity. Rosiglitazone was used as a positive control. After 24 hours, rosiglitazone increased PPAR␥ transcriptional activity by 41%, whereas uPA induced a significant decrease by 37%. Moreover, uPA completely reversed the rosiglitazone-stimulated PPAR␥ transcriptional activity ( Figure 4D ). Furthermore, inhibition of MEK by the addition of PD98059 did not significantly change either the basal or the rosiglitazone-driven transcriptional activity of PPAR␥, but it completely prevented the inhibitory effect of uPA on both the basal and the rosiglitazone-stimulated PPAR␥ activity ( Figure 4D ). Taken together, these results suggest that MEK activation by uPA may play a role in the inactivation of PPAR␥ activity and subsequently on the downregulation of PON1 gene expression.
uPA Induces PPAR␥ Nuclear Export in a MEK-Dependent Manner
PPAR␥ is localized and functions primarily in the nucleus. However, it can redistribute to different compartments under distinct physiological conditions. On the contrary, MEK was shown to localize in the cytosol of resting cells, and it can translocate into the nucleus on cellular stimulation. 27 Recent studies have demonstrated that MEK1 interacts with PPAR␥ resulting in nuclear export and downregulation of PPAR␥ transcriptional activity. 28 On the basis of these findings, we next sought to determine whether uPA downregulates PON1 expression via PPAR␥ export from the nucleus and whether this effect depends on MEK activation. HuH7 hepatocytes were stimulated with uPA for 24 hours in the absence or presence of leptomycin B (LMB), which is a potent inhibitor of nuclear export. LMB abolished the inhibitory effect of uPA on both PON1 mRNA expression ( Figure 5A ) and on PPAR␥ transcriptional activity ( Figure 5B ) in a dose-dependent manner. These results suggest that uPA induces export of PPAR␥ out of the nucleus. To confirm these results, we designed primers and analyzed binding of PPAR␥ to the PON1gene promoter by chromatin immunoprecipitation assays. Chromatin immunoprecipitation analysis clearly showed that in resting HuH7cells PPAR␥ could directly bind to PON1 promoter regions. Treatment of the cells with uPA induced a significant release of PPAR␥ from PON1 promoter ( Figure 5C ). Immunoprecipitation of PPAR␥ from cytosolic fractions followed by immunoblotting with anti-PPAR␥ antibody confirmed that PPAR␥ abundance in the cytosol increases after stimulation of the cells with uPA ( Figure 5D ). Furthermore, immunocytochemistry studies clearly demonstrated that uPA induces redistribution of PPAR␥ from the nucleus to the cytoplasmic compartment, and this effect is prevented by LMB, as well as by the MEK1 inhibitor PD98059 ( Figure 5E and Supplemental Figure IVA and IVB, respectively), indicating that MEK is involved in mediating this action. Distribution of tubulin as a cytosolic fraction marker and histone H3 as a nuclear fraction marker in subcellular fractions used for cytosolic immunoprecipitation showed fraction purity and are shown in Supplemental Figure IVC .
Next, by performing coimmunoprecipitation studies, we examined whether uPA-induced relocalization of PPAR␥ is mediated by a direct protein-protein interaction between MEK and PPAR␥. HuH7 cells were exposed to uPA for 20 or 60 minutes in the absence or presence of LMB or in the presence of the MEK inhibitors. Then, PPAR␥ was immunoprecipitated from cytosolic fractions, and MEK protein was determined by Western blotting. The abundance of PPAR␥ was similar in whole cell lysates ( Figure 6A ). Association of PPAR␥ with MEK was almost completely absent in the cytosolic fraction from nonstimulated cells. However, 20 minutes after stimulation with uPA, PPAR␥ coimmunoprecipitated with MEK. LMB or the MEK inhibitors PD98059 or U0126 prevented the nucleocytosolic redistribution of PPAR␥ on uPA stimulation. It is noteworthy however, that LMB or U0126 alone slightly increased the basal level of PPAR␥-MEK complex in the cytosol, but this is not surprising, as changes of basal levels can be observed often when unspecific inhibitors are used. Next, Figure 6B presents evidence that MEK was present in the nucleus of cells after stimulation with uPA in the presence of LMB, thus supporting our hypothesis that uPA stimulates MEK translocation from cytosol to the nucleus, where it interacts with PPAR␥ and induces PPAR␥ nuclear export to the cytosol.
To support the results obtained with the HuH7 cell line, which is a hepatocellular carcinoma, we evaluated the effect of uPA on PON1 expression in primary hepatocytes isolated from rat liver, as rat and human uPA/uPAR cross-react. 29 PON1 mRNA expression was significantly reduced by 76% in primary hepatocytes incubated for 18 hours with uPA, and this effect was abolished when MEK activation was inhibited by PD98059 or when nuclear export was inhibited by LMB (Supplemental Figure V) . These results support our hypothesis and confirm the fundamental changes in hepatocyte PON1 expression on uPA stimulation and the involvement of the MEK pathway in this process.
Discussion
This study provides the first evidence that uPA interferes with PPAR␥ transcriptional activity in hepatocytes resulting in downregulation of PON1 expression and its secretion to the medium. Our results fit a model (Figure 7 ) in which uPA, via its interaction with uPAR on the hepatocyte surface, stimulates MEK interaction with PPAR␥ in the nucleus, leading to export of the nuclear PPAR␥ to the cytosol. As a result, hepatic PON1 gene transcription is reduced. This effect was demonstrated in the HuH7 hepatocyte cell line, as well as in primary rat hepatocytes, thus reflecting the physiological importance of our results.
Previous studies reviewed recently by D'Alessio and Blasi 30 have shown that uPA interaction with uPAR activates intracellular signaling molecules such as tyrosine-and serine-protein kinases, Src, focal adhesion kinase, Rac, ERK/mitogen-activated protein kinase, and JAK/STAT, all of which are part of a large "signalosome" and affect the transcriptional activities of very many genes. However, to the best of our knowledge, the present study reports for the first time that uPA affects PPAR␥ transcriptional activity. By using the chromatin immunoprecipitation assay, we have shown for the first time that PPAR␥ binds to DNA sequences in the PON1 promoter region and that uPA reduces the association of PPAR␥ to PON1 promoter.
The mechanism whereby uPA inhibits PON1 gene expression via MEK activation was confirmed using several distinct experimental approaches, and findings are in accordance with previous reports 27 showing that MEK, which is localized in the cytosol of resting cells, translocate to the nucleus on cellular stimulation, where it directly interacts with PPAR␥, followed by rapid export out of the nucleus to the cytoplasmic compartment. 28 However, because activation of MEK1 also leads to activation of the downstream ERK1/2, which was shown to phosphorylate Ser84/Ser112 within PPAR␥ and prevent its activity, 31 it cannot be excluded that ERK1/2-mediated phosphorylation of PPAR␥ may also play a part in the inhibitory effect of uPA on PON1 hepatic expression. Nevertheless, because in our hands inhibition of nuclear export by LMB was able to completely prevent the inhibitory effect of uPA on both PON1 mRNA expression and PPAR␥ transcriptional activity, it is more likely that the interaction between MEK and PPAR␥ in the nucleus is important for the suppression of PON1 expression by uPA.
Studies using uPAR Ϫ/Ϫ mice evidenced the role of uPAR in uPA-mediated downregulation of hepatic PON1 expression in vivo. However, uPAR is a glycosylphosphatidylinositolanchored protein that lacks a transmembrane domain, and its biological functions rely on its interaction with other cell surface and transmembrane proteins. Considering that uPA binding to uPAR initiates the formation of multiprotein complexes, which are cell type specific and may contain different adaptor proteins, such as integrins, low-density lipoprotein-related protein, epidermal growth factor receptor, and platelet-derived growth factor receptor-␤, 16, 18 it is hard to predict which adaptor protein could possibly mediate the effect of uPA-uPAR interaction on PON1 expression in hepatocytes. This question will be pursued experimentally in future investigations.
To strengthen the in vitro results obtained in HuH7 hepatocytes, we determined PON1 mRNA abundance in liver tissue from the uPAR Ϫ/Ϫ mice in comparison with control mice. However, as the liver is formed by parenchymal cells (hepatocytes) and nonparenchymal cells, analysis of whole liver RNA may reflect the contribution of both cell types to PON1 mRNA. In contrast to hepatocytes, which occupy 80% of total liver volume and perform the majority of liver functions, nonparenchymal liver cells contribute only 6.5% to the liver volume but 40% of total number of liver cells, are localized in the sinusoidal compartment of the tissue, and were shown to regulate many of the neighboring hepatocyte functions by secreted substances. 32 Therefore, we tend to believe that PON1 mRNA expression in liver tissue represent mainly the contribution of the parenchymal hepatocytes, whereas the nonparenchymal cells may serve for a possible local source of uPA in vivo. Although under normal conditions liver cells produce minimal levels of uPA, under pathological conditions the hepatocytes may be exposed to reactive oxygen species or inflammatory cytokines produced by liver sinusoidal cells, including macrophages, both of which were shown to remarkably increase uPA production. 3334 Thus, although plasma concentration of uPA is around 20 pmol/L, the local concentration of uPA under pathological conditions is expected to be substantially greater than that in the circulation and may account for our observations at saturating uPA levels.
uPA downregulation of PON1 gene expression in hepatocytes sustains uPA proatherogenicity, as many studies have shown that low levels of PON1 predispose to vascular inflammation and oxidative stress. 35 PON1 is hypothesized to be an important determinant of the antiatherogenic functions of HDL, which are associated with the enzyme's capability to protect low-density lipoprotein, 36 as well as HDL, 37 from oxidation, to decrease macrophage oxidative status, 38 to stimulate cholesterol efflux from macrophages, 39 to decrease oxidative status in atherosclerotic lesions, 4 and to confer cytoprotection against apoptosis by upregulating macrophage scavenger receptor B-I. 40 Thus, decreased PON1 release from the liver in response to uPA would appear to be deleterious and promoting atherogenesis. Recent lines of evidence appear to support the notion that uPA overexpression contributes to the progression and complications of atherosclerosis. 41 The atherogenic effects of uPA could be mediated via plasminogen activation, as well as via interaction with uPAR. 42 In a mouse transgenic model, macrophage-specific uPA overexpression accelerated atherosclerosis by stimulation of lesion progression and accumulation of lipids in early lesions, and these effects were largely independent of uPAR. 43 However, in the absence of uPA overexpression, uPAR contributed modestly to atherosclerosis. Our study suggests that the uPA-uPAR interaction may be an important contributor to atherogenesis, and the increased serum PON1 activity and decreased oxidative stress shown in uPAR Ϫ/Ϫ mice could account, at least in part, for the reported resistance of low-density lipoprotein receptor Ϫ/Ϫ / uPAR Ϫ/Ϫ double knockout mice to high-fat diet-induced atherosclerosis. 43 In summary, this study has important implications for understanding the ability of uPA to modulate oxidative stress, and it gives more insight into the influence of uPA on atherogenesis. Figure 7 . Model for the mechanism by which urokinase-type plasminogen activator (uPA) suppresses hepatic paraoxonase 1 (PON1) gene transcription. In resting cells, mitogen-activated protein kinase kinase (MEK) is localized in the cytosol and peroxisome proliferator-activated receptor-␥ (PPAR␥) mainly in the nucleus. uPA, via binding to uPA receptor (uPAR), activates MEK, which then translocates to the nucleus, interacts with PPAR␥, and induces export of the nuclear PPAR␥ to the cytosol. As a result, PON1 gene transcription is suppressed.
